메뉴 건너뛰기




Volumn 54, Issue 2, 2015, Pages 147-166

Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARYLDIALKYLPHOSPHATASE 1; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P-450 CYP2C19; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84925488457     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0230-6     Document Type: Review
Times cited : (162)

References (200)
  • 1
    • 84856158305 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
    • PID: 21873419
    • Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.
    • (2011) Eur Heart J. , vol.32 , Issue.23 , pp. 2999-3054
    • Hamm, C.W.1    Bassand, J.P.2    Agewall, S.3    Bax, J.4    Boersma, E.5    Bueno, H.6
  • 2
    • 84855396777 scopus 로고    scopus 로고
    • Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association
    • PID: 22215894
    • Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–97.
    • (2012) Circulation. , vol.125 , Issue.1 , pp. 188-197
    • Roger, V.L.1    Go, A.S.2    Lloyd-Jones, D.M.3    Benjamin, E.J.4    Berry, J.D.5    Borden, W.B.6
  • 3
    • 34047096264 scopus 로고    scopus 로고
    • Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
    • COI: 1:CAS:528:DC%2BD2sXjvFGgt7s%3D, PID: 17418288
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16.
    • (2007) J Am Coll Cardiol. , vol.49 , Issue.14 , pp. 1505-1516
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Alfonso, F.4    Macaya, C.5    Bass, T.A.6
  • 4
    • 83155173178 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
    • COI: 1:CAS:528:DC%2BC38Xhs1ChsL4%3D, PID: 21689142
    • Kelly RP, Close SL, Farid NA, Winters KJ, Shen L, Natanegara F, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol. 2012;73(1):93–105.
    • (2012) Br J Clin Pharmacol. , vol.73 , Issue.1 , pp. 93-105
    • Kelly, R.P.1    Close, S.L.2    Farid, N.A.3    Winters, K.J.4    Shen, L.5    Natanegara, F.6
  • 5
    • 80054054702 scopus 로고    scopus 로고
    • Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP-GPRD)
    • COI: 1:CAS:528:DC%2BC3MXht1Oitb7P, PID: 21875855
    • Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. 2011;32(19):2376–86.
    • (2011) Eur Heart J. , vol.32 , Issue.19 , pp. 2376-2386
    • Boggon, R.1    van Staa, T.P.2    Timmis, A.3    Hemingway, H.4    Ray, K.K.5    Begg, A.6
  • 6
    • 33947718387 scopus 로고    scopus 로고
    • Role of clopidogrel in managing atherothrombotic cardiovascular disease
    • PID: 17371888
    • Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med. 2007;146(6):434–41.
    • (2007) Ann Intern Med. , vol.146 , Issue.6 , pp. 434-441
    • Eshaghian, S.1    Kaul, S.2    Amin, S.3    Shah, P.K.4    Diamond, G.A.5
  • 7
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • COI: 1:CAS:528:DC%2BD3MXms1arsrY%3D, PID: 11519503
    • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
    • (2001) N Engl J Med. , vol.345 , Issue.7 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 8
    • 84866368808 scopus 로고    scopus 로고
    • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines
    • PID: 22809746
    • Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–81.
    • (2012) J Am Coll Cardiol. , vol.60 , Issue.7 , pp. 645-681
    • Jneid, H.1    Anderson, J.L.2    Wright, R.S.3    Adams, C.D.4    Bridges, C.R.5    Casey, D.E.6
  • 9
    • 84872698656 scopus 로고    scopus 로고
    • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines
    • PID: 23256914
    • American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.
    • (2013) J Am Coll Cardiol , vol.61 , Issue.4 , pp. e78-e140
    • American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions,1    O’Gara, P.T.2    Kushner, F.G.3    Ascheim, D.D.4
  • 10
    • 84880899280 scopus 로고    scopus 로고
    • Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    • COI: 1:CAS:528:DC%2BC3sXhtValtbzI, PID: 23697979
    • Perry CG, Shuldiner AR. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet. 2013;58(6):339–45.
    • (2013) J Hum Genet. , vol.58 , Issue.6 , pp. 339-345
    • Perry, C.G.1    Shuldiner, A.R.2
  • 11
    • 34249990913 scopus 로고    scopus 로고
    • Clopidogrel resistance?
    • COI: 1:CAS:528:DC%2BD2sXmtlaitrc%3D, PID: 17109936
    • Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120(3):311–21.
    • (2007) Thromb Res. , vol.120 , Issue.3 , pp. 311-321
    • Gurbel, P.A.1    Tantry, U.S.2
  • 12
    • 73149119363 scopus 로고    scopus 로고
    • Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    • COI: 1:CAS:528:DC%2BD1MXhs1aqsr7L, PID: 19812348
    • Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92–9.
    • (2010) Drug Metab Dispos. , vol.38 , Issue.1 , pp. 92-99
    • Kazui, M.1    Nishiya, Y.2    Ishizuka, T.3    Hagihara, K.4    Farid, N.A.5    Okazaki, O.6
  • 13
    • 84977775504 scopus 로고    scopus 로고
    • (FDA). FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug
    • US Food and Drug Administration (FDA). FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Rockville: FDA; 2010.
    • (2010) Rockville: FDA
    • Food, U.S.1    Administration, D.2
  • 14
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • COI: 1:CAS:528:DC%2BD1MXhtVCnt7zL, PID: 19706858
    • Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.
    • (2009) JAMA. , vol.302 , Issue.8 , pp. 849-857
    • Shuldiner, A.R.1    O’Connell, J.R.2    Bliden, K.P.3    Gandhi, A.4    Ryan, K.5    Horenstein, R.B.6
  • 15
    • 84859181019 scopus 로고    scopus 로고
    • Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
    • COI: 1:CAS:528:DC%2BC38Xot1ynsLk%3D, PID: 22260716
    • Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012;10(4):529–42.
    • (2012) J Thromb Haemost. , vol.10 , Issue.4 , pp. 529-542
    • Siller-Matula, J.M.1    Delle-Karth, G.2    Lang, I.M.3    Neunteufl, T.4    Kozinski, M.5    Kubica, J.6
  • 16
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • COI: 1:CAS:528:DC%2BD1MXhtVSlsbY%3D, PID: 19106083
    • Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.
    • (2009) N Engl J Med. , vol.360 , Issue.4 , pp. 363-375
    • Simon, T.1    Verstuyft, C.2    Mary-Krause, M.3    Quteineh, L.4    Drouet, E.5    Meneveau, N.6
  • 17
    • 33749339075 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    • COI: 1:CAS:528:DC%2BD28XhtVCgur7I, PID: 16772608
    • Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–7.
    • (2006) Blood. , vol.108 , Issue.7 , pp. 2244-2247
    • Hulot, J.S.1    Bura, A.2    Villard, E.3    Azizi, M.4    Remones, V.5    Goyenvalle, C.6
  • 18
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • COI: 1:CAS:528:DC%2BD1MXhtVSlsbs%3D, PID: 19106084
    • Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62.
    • (2009) N Engl J Med. , vol.360 , Issue.4 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3    Shen, L.4    Hockett, R.D.5    Brandt, J.T.6
  • 19
    • 84874550138 scopus 로고    scopus 로고
    • Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function
    • COI: 1:CAS:528:DC%2BC3sXht1Gmsrg%3D, PID: 23333143
    • Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872–9.
    • (2013) J Am Coll Cardiol. , vol.61 , Issue.8 , pp. 872-879
    • Frelinger, A.L.1    Bhatt, D.L.2    Lee, R.D.3    Mulford, D.J.4    Wu, J.5    Nudurupati, S.6
  • 20
    • 84925514862 scopus 로고    scopus 로고
    • Sanofi Pharmaceuticals. Plavix® US Prescribing Information [CLO-FPLR-SL-DEC13]. 2013. Accessed 23 Dec 2014
    • Sanofi Pharmaceuticals. Plavix® US Prescribing Information [CLO-FPLR-SL-DEC13]. 2013. http://products.sanofi.us/plavix/plavix.html. Accessed 23 Dec 2014.
  • 22
    • 77953911457 scopus 로고    scopus 로고
    • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    • COI: 1:CAS:528:DC%2BC3cXhtlWjt7jJ, PID: 20828644
    • Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–33.
    • (2010) J Am Coll Cardiol. , vol.56 , Issue.12 , pp. 919-933
    • Bonello, L.1    Tantry, U.S.2    Marcucci, R.3    Blindt, R.4    Angiolillo, D.J.5    Becker, R.6
  • 24
  • 25
    • 84855199955 scopus 로고    scopus 로고
    • A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma
    • COI: 1:CAS:528:DC%2BC3MXhs1ykurvL
    • Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD. A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2012;880(1):132–9.
    • (2012) J Chromatogr B Anal Technol Biomed Life Sci. , vol.880 , Issue.1 , pp. 132-139
    • Peer, C.J.1    Spencer, S.D.2    VanDenBerg, D.A.3    Pacanowski, M.A.4    Horenstein, R.B.5    Figg, W.D.6
  • 26
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial
    • von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation. 2005;112(19):2946–50.
    • (2005) Circulation. , vol.112 , Issue.19 , pp. 2946-2950
    • von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3    Schomig, E.4    Kastrati, A.5    Schomig, A.6
  • 27
    • 0032797781 scopus 로고    scopus 로고
    • Pharmacokinetics of clopidogrel
    • COI: 1:CAS:528:DyaK1MXltVKmurY%3D, PID: 10440419
    • Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25(Suppl 2):25–8.
    • (1999) Semin Thromb Hemost. , vol.25 , pp. 25-28
    • Caplain, H.1    Donat, F.2    Gaud, C.3    Necciari, J.4
  • 28
    • 37849002889 scopus 로고    scopus 로고
    • Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    • COI: 1:CAS:528:DC%2BD1cXis1Sqtr8%3D, PID: 18055486
    • Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21–30.
    • (2008) Eur Heart J. , vol.29 , Issue.1 , pp. 21-30
    • Wallentin, L.1    Varenhorst, C.2    James, S.3    Erlinge, D.4    Braun, O.O.5    Jakubowski, J.A.6
  • 29
    • 79955116606 scopus 로고    scopus 로고
    • High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
    • PID: 21511218
    • Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv. 2011;4(4):392–402.
    • (2011) JACC Cardiovasc Interv. , vol.4 , Issue.4 , pp. 392-402
    • Collet, J.P.1    Hulot, J.S.2    Anzaha, G.3    Pena, A.4    Chastre, T.5    Caron, C.6
  • 30
    • 84904020763 scopus 로고    scopus 로고
    • Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
    • PID: 24710841
    • Horenstein RB, Madabushi R, Zineh I, Yerges-Armstrong LM, Peer CJ, Schuck RN, et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54(8):865–73.
    • (2014) J Clin Pharmacol. , vol.54 , Issue.8 , pp. 865-873
    • Horenstein, R.B.1    Madabushi, R.2    Zineh, I.3    Yerges-Armstrong, L.M.4    Peer, C.J.5    Schuck, R.N.6
  • 31
    • 78349232464 scopus 로고    scopus 로고
    • Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel
    • COI: 1:CAS:528:DC%2BC3MXltlGntQ%3D%3D, PID: 21053990
    • Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clinical Pharmacokinetics. 2010;49(12):777–98.
    • (2010) Clinical Pharmacokinetics. , vol.49 , Issue.12 , pp. 777-798
    • Small, D.S.1    Farid, N.A.2    Payne, C.D.3    Konkoy, C.S.4    Jakubowski, J.A.5    Winters, K.J.6
  • 32
    • 84858127301 scopus 로고    scopus 로고
    • High platelet reactivity and antiplatelet therapy resistance
    • COI: 1:CAS:528:DC%2BC38XmsFCitLs%3D, PID: 22422334
    • Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost. 2012;38(2):200–12.
    • (2012) Semin Thromb Hemost. , vol.38 , Issue.2 , pp. 200-212
    • Linden, M.D.1    Tran, H.2    Woods, R.3    Tonkin, A.4
  • 34
    • 35549008493 scopus 로고    scopus 로고
    • Platelet function monitoring in patients with coronary artery disease
    • COI: 1:CAS:528:DC%2BD2sXht1Glur%2FE, PID: 17980247
    • Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822–34.
    • (2007) J Am Coll Cardiol. , vol.50 , Issue.19 , pp. 1822-1834
    • Gurbel, P.A.1    Becker, R.C.2    Mann, K.G.3    Steinhubl, S.R.4    Michelson, A.D.5
  • 35
    • 70249101426 scopus 로고    scopus 로고
    • Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the Platelet Physiology Subcommittee of the SSC of the ISTH
    • COI: 1:STN:280:DC%2BD1MvjvVWnsA%3D%3D, PID: 19422455
    • Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the Platelet Physiology Subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009;7(6):1029.
    • (2009) J Thromb Haemost. , vol.7 , Issue.6 , pp. 1029
    • Cattaneo, M.1    Hayward, C.P.2    Moffat, K.A.3    Pugliano, M.T.4    Liu, Y.5    Michelson, A.D.6
  • 36
    • 79961072519 scopus 로고    scopus 로고
    • High platelet reactivity and clinical outcome—fact and fiction
    • COI: 1:CAS:528:DC%2BC3MXhtFKntrjI, PID: 21505714
    • Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome—fact and fiction. Thromb Haemost. 2011;106(2):191–202.
    • (2011) Thromb Haemost. , vol.106 , Issue.2 , pp. 191-202
    • Sibbing, D.1    Byrne, R.A.2    Bernlochner, I.3    Kastrati, A.4
  • 37
    • 70349510067 scopus 로고    scopus 로고
    • Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients
    • COI: 1:CAS:528:DC%2BD1MXht1WntbnN, PID: 19801028
    • Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol. 2009;104(8):1078–82.
    • (2009) Am J Cardiol. , vol.104 , Issue.8 , pp. 1078-1082
    • Cuisset, T.1    Frere, C.2    Quilici, J.3    Gaborit, B.4    Castelli, C.5    Poyet, R.6
  • 38
    • 84904899573 scopus 로고    scopus 로고
    • Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial
    • PID: 25060370
    • Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, et al. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014;64(4):361–8.
    • (2014) J Am Coll Cardiol. , vol.64 , Issue.4 , pp. 361-368
    • Hochholzer, W.1    Ruff, C.T.2    Mesa, R.A.3    Mattimore, J.F.4    Cyr, J.F.5    Lei, L.6
  • 39
    • 84861494090 scopus 로고    scopus 로고
    • Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study
    • COI: 1:CAS:528:DC%2BC38Xnslagtbk%3D, PID: 22624833
    • Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012;59(22):1928–37.
    • (2012) J Am Coll Cardiol. , vol.59 , Issue.22 , pp. 1928-1937
    • Price, M.J.1    Murray, S.S.2    Angiolillo, D.J.3    Lillie, E.4    Smith, E.N.5    Tisch, R.L.6
  • 40
    • 84873086640 scopus 로고    scopus 로고
    • Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents
    • PID: 23260377
    • Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Int J Cardiol. 2013;163(1):79–86.
    • (2013) Int J Cardiol. , vol.163 , Issue.1 , pp. 79-86
    • Park, J.J.1    Park, K.W.2    Kang, J.3    Jeon, K.H.4    Kang, S.H.5    Ahn, H.S.6
  • 41
    • 77952591958 scopus 로고    scopus 로고
    • Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    • COI: 1:CAS:528:DC%2BC3cXptVyqs7s%3D, PID: 20510210
    • Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427–34.
    • (2010) J Am Coll Cardiol. , vol.55 , Issue.22 , pp. 2427-2434
    • Hochholzer, W.1    Trenk, D.2    Fromm, M.F.3    Valina, C.M.4    Stratz, C.5    Bestehorn, H.P.6
  • 42
    • 84875924518 scopus 로고    scopus 로고
    • Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes
    • COI: 1:CAS:528:DC%2BC3sXmsVGmsb4%3D, PID: 23364775
    • Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, et al. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013;109(4):744–54.
    • (2013) Thromb Haemost. , vol.109 , Issue.4 , pp. 744-754
    • Carlquist, J.F.1    Knight, S.2    Horne, B.D.3    Huntinghouse, J.A.4    Rollo, J.S.5    Muhlestein, J.B.6
  • 43
    • 84860821268 scopus 로고    scopus 로고
    • Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent
    • PID: 22147885
    • Roth GA, Morden NE, Zhou W, Malenka DJ, Skinner J. Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. Circ Cardiovasc Qual Outcomes. 2012;5(1):103–12.
    • (2012) Circ Cardiovasc Qual Outcomes. , vol.5 , Issue.1 , pp. 103-112
    • Roth, G.A.1    Morden, N.E.2    Zhou, W.3    Malenka, D.J.4    Skinner, J.5
  • 44
    • 17844373254 scopus 로고    scopus 로고
    • Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
    • COI: 1:CAS:528:DC%2BD2MXjvFKiu7w%3D, PID: 15870416
    • Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30.
    • (2005) JAMA. , vol.293 , Issue.17 , pp. 2126-2130
    • Iakovou, I.1    Schmidt, T.2    Bonizzoni, E.3    Ge, L.4    Sangiorgi, G.M.5    Stankovic, G.6
  • 45
    • 59749090008 scopus 로고    scopus 로고
    • Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BD1MXhtlKgtr0%3D, PID: 19147609
    • Iijima R, Ndrepepa G, Mehilli J, Byrne RA, Schulz S, Neumann FJ, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J. 2009;30(3):290–6.
    • (2009) Eur Heart J. , vol.30 , Issue.3 , pp. 290-296
    • Iijima, R.1    Ndrepepa, G.2    Mehilli, J.3    Byrne, R.A.4    Schulz, S.5    Neumann, F.J.6
  • 46
    • 79551530662 scopus 로고    scopus 로고
    • Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study
    • COI: 1:CAS:528:DC%2BC3MXjsFOmtbc%3D, PID: 21275437
    • Cay S, Cagirci G, Aydogdu S, Balbay Y, Sen N, Maden O, et al. Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Drugs Aging. 2011;28(2):119–29.
    • (2011) Drugs Aging. , vol.28 , Issue.2 , pp. 119-129
    • Cay, S.1    Cagirci, G.2    Aydogdu, S.3    Balbay, Y.4    Sen, N.5    Maden, O.6
  • 47
    • 11144355993 scopus 로고    scopus 로고
    • Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
    • PID: 15152138
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol. 2004;16(4):169–74.
    • (2004) J Invasive Cardiol , vol.16 , Issue.4 , pp. 169-174
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Barrera Ramirez, C.4    Sabate, M.5    Fernandez, C.6
  • 48
    • 84904726025 scopus 로고    scopus 로고
    • Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients
    • COI: 1:CAS:528:DC%2BC2cXhtFansr7N, PID: 24043374
    • Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, et al. Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis. 2014;38(2):127–36.
    • (2014) J Thromb Thrombolysis. , vol.38 , Issue.2 , pp. 127-136
    • Wagner, H.1    Angiolillo, D.J.2    Ten Berg, J.M.3    Bergmeijer, T.O.4    Jakubowski, J.A.5    Small, D.S.6
  • 51
    • 79953321263 scopus 로고    scopus 로고
    • Depot-specific expression of lipolytic genes in human adipose tissues—association among CES1 expression, triglyceride lipase activity and adiposity
    • COI: 1:CAS:528:DC%2BC3MXltVantL8%3D, PID: 21081832
    • Nagashima S, Yagyu H, Takahashi N, Kurashina T, Takahashi M, Tsuchita T, et al. Depot-specific expression of lipolytic genes in human adipose tissues—association among CES1 expression, triglyceride lipase activity and adiposity. J Atheroscler Thromb. 2011;18(3):190–9.
    • (2011) J Atheroscler Thromb. , vol.18 , Issue.3 , pp. 190-199
    • Nagashima, S.1    Yagyu, H.2    Takahashi, N.3    Kurashina, T.4    Takahashi, M.5    Tsuchita, T.6
  • 52
    • 78049441468 scopus 로고    scopus 로고
    • Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry
    • PID: 20630460
    • Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv. 2010;3(6):660–8.
    • (2010) JACC Cardiovasc Interv. , vol.3 , Issue.6 , pp. 660-668
    • Lancefield, T.1    Clark, D.J.2    Andrianopoulos, N.3    Brennan, A.L.4    Reid, C.M.5    Johns, J.6
  • 53
    • 64849092007 scopus 로고    scopus 로고
    • The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease
    • PID: 19233855
    • Mak KH, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, et al. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 2009;30(7):857–65.
    • (2009) Eur Heart J. , vol.30 , Issue.7 , pp. 857-865
    • Mak, K.H.1    Bhatt, D.L.2    Shao, M.3    Haffner, S.M.4    Hamm, C.W.5    Hankey, G.J.6
  • 54
    • 75349091412 scopus 로고    scopus 로고
    • The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with biolimus- and sirolimus-eluting stents (from the LEADERS trial)
    • COI: 1:CAS:528:DC%2BC3cXhs1Ogsb4%3D, PID: 20152241
    • Sarno G, Garg S, Onuma Y, Buszman P, Linke A, Ischinger T, et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with biolimus- and sirolimus-eluting stents (from the LEADERS trial). Am J Cardiol. 2010;105(4):475–9.
    • (2010) Am J Cardiol. , vol.105 , Issue.4 , pp. 475-479
    • Sarno, G.1    Garg, S.2    Onuma, Y.3    Buszman, P.4    Linke, A.5    Ischinger, T.6
  • 55
    • 51449118219 scopus 로고    scopus 로고
    • Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel
    • COI: 1:CAS:528:DC%2BD1cXhtFekurfO, PID: 18848137
    • Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008;52(13):1052–9.
    • (2008) J Am Coll Cardiol. , vol.52 , Issue.13 , pp. 1052-1059
    • Ang, L.1    Palakodeti, V.2    Khalid, A.3    Tsimikas, S.4    Idrees, Z.5    Tran, P.6
  • 56
    • 34547906405 scopus 로고    scopus 로고
    • Diabetes and mortality following acute coronary syndromes
    • COI: 1:CAS:528:DC%2BD2sXpt1ahsbw%3D, PID: 17699010
    • Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298(7):765–75.
    • (2007) JAMA. , vol.298 , Issue.7 , pp. 765-775
    • Donahoe, S.M.1    Stewart, G.C.2    McCabe, C.H.3    Mohanavelu, S.4    Murphy, S.A.5    Cannon, C.P.6
  • 57
    • 84858340502 scopus 로고    scopus 로고
    • CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BC38XjvVWqsbg%3D, PID: 21831410
    • Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res. 2012;129(4):441–6.
    • (2012) Thromb Res. , vol.129 , Issue.4 , pp. 441-446
    • Kassimis, G.1    Davlouros, P.2    Xanthopoulou, I.3    Stavrou, E.F.4    Athanassiadou, A.5    Alexopoulos, D.6
  • 58
    • 79960160555 scopus 로고    scopus 로고
    • Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
    • COI: 1:CAS:528:DC%2BC3MXhtV2qsr3F, PID: 21628721
    • Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart. 2011;97(15):1239–44.
    • (2011) Heart. , vol.97 , Issue.15 , pp. 1239-1244
    • Bouman, H.J.1    Harmsze, A.M.2    van Werkum, J.W.3    Breet, N.J.4    Bergmeijer, T.O.5    Ten Cate, H.6
  • 59
    • 35348913868 scopus 로고    scopus 로고
    • Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial
    • PID: 17950791
    • Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364–9.
    • (2007) Am J Cardiol. , vol.100 , Issue.9 , pp. 1364-1369
    • Feit, F.1    Voeltz, M.D.2    Attubato, M.J.3    Lincoff, A.M.4    Chew, D.P.5    Bittl, J.A.6
  • 60
    • 84860879920 scopus 로고    scopus 로고
    • No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting
    • COI: 1:CAS:528:DC%2BC38XnvVKnsbk%3D, PID: 22298798, (S1–2)
    • Jaitner J, Morath T, Byrne RA, Braun S, Gebhard D, Bernlochner I, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2012;5(1):82–8 (S1–2).
    • (2012) Circ Cardiovasc Interv , vol.5 , Issue.1 , pp. 82-88
    • Jaitner, J.1    Morath, T.2    Byrne, R.A.3    Braun, S.4    Gebhard, D.5    Bernlochner, I.6
  • 61
    • 77957792195 scopus 로고    scopus 로고
    • CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
    • COI: 1:CAS:528:DC%2BC3cXhsF2rs7jE, PID: 20833683
    • Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010;31(24):3046–53.
    • (2010) Eur Heart J. , vol.31 , Issue.24 , pp. 3046-3053
    • Harmsze, A.M.1    van Werkum, J.W.2    Ten Berg, J.M.3    Zwart, B.4    Bouman, H.J.5    Breet, N.J.6
  • 62
    • 33846504706 scopus 로고    scopus 로고
    • A “silent” polymorphism in the MDR1 gene changes substrate specificity
    • COI: 1:CAS:528:DC%2BD2sXotFCitA%3D%3D, PID: 17185560
    • Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525–8.
    • (2007) Science. , vol.315 , Issue.5811 , pp. 525-528
    • Kimchi-Sarfaty, C.1    Oh, J.M.2    Kim, I.W.3    Sauna, Z.E.4    Calcagno, A.M.5    Ambudkar, S.V.6
  • 63
    • 77952048536 scopus 로고    scopus 로고
    • The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    • COI: 1:CAS:528:DC%2BC3cXntlGlsbY%3D, PID: 20352154
    • Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 2010;103(5):920–5.
    • (2010) Thromb Haemost. , vol.103 , Issue.5 , pp. 920-925
    • Harmsze, A.M.1    Robijns, K.2    van Werkum, J.W.3    Breet, N.J.4    Hackeng, C.M.5    Ten Berg, J.M.6
  • 64
    • 77958105401 scopus 로고    scopus 로고
    • Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    • COI: 1:CAS:528:DC%2BC3cXht12ks7jF, PID: 20801494
    • Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–9.
    • (2010) Lancet. , vol.376 , Issue.9749 , pp. 1312-1319
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3    Shen, L.4    Walker, J.R.5    Simon, T.6
  • 65
    • 84855958154 scopus 로고    scopus 로고
    • Predicting clopidogrel response using DNA samples linked to an electronic health record
    • COI: 1:CAS:528:DC%2BC38Xht1Wkurw%3D, PID: 22190063
    • Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther. 2012;91(2):257–63.
    • (2012) Clin Pharmacol Ther. , vol.91 , Issue.2 , pp. 257-263
    • Delaney, J.T.1    Ramirez, A.H.2    Bowton, E.3    Pulley, J.M.4    Basford, M.A.5    Schildcrout, J.S.6
  • 66
    • 84867301073 scopus 로고    scopus 로고
    • ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis
    • COI: 1:CAS:528:DC%2BC38XhsFKjtb%2FM, PID: 23056288
    • Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):e46366.
    • (2012) PLoS One. , vol.7 , Issue.10 , pp. e46366
    • Su, J.1    Xu, J.2    Li, X.3    Zhang, H.4    Hu, J.5    Fang, R.6
  • 67
    • 84861329078 scopus 로고    scopus 로고
    • ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis
    • COI: 1:CAS:528:DC%2BC38XntlyrsLc%3D, PID: 22209339
    • Luo M, Li J, Xu X, Sun X, Sheng W. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb Res. 2012;129(6):754–9.
    • (2012) Thromb Res. , vol.129 , Issue.6 , pp. 754-759
    • Luo, M.1    Li, J.2    Xu, X.3    Sun, X.4    Sheng, W.5
  • 68
    • 84871919080 scopus 로고    scopus 로고
    • The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
    • COI: 1:CAS:528:DC%2BC38XhvVWhtrzM, PID: 23111421
    • Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23(1):1–8.
    • (2013) Pharmacogenet Genomics. , vol.23 , Issue.1 , pp. 1-8
    • Lewis, J.P.1    Horenstein, R.B.2    Ryan, K.3    O’Connell, J.R.4    Gibson, Q.5    Mitchell, B.D.6
  • 69
    • 28444456318 scopus 로고    scopus 로고
    • A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity
    • COI: 1:CAS:528:DC%2BD28Xkt1Cksw%3D%3D, PID: 16419644
    • Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res. 2005;28(9):719–25.
    • (2005) Hypertens Res. , vol.28 , Issue.9 , pp. 719-725
    • Geshi, E.1    Kimura, T.2    Yoshimura, M.3    Suzuki, H.4    Koba, S.5    Sakai, T.6
  • 70
    • 84896400298 scopus 로고    scopus 로고
    • The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease
    • COI: 1:CAS:528:DC%2BC2cXjs1Gqurs%3D, PID: 24535487
    • Xie C, Ding X, Gao J, Wang H, Hang Y, Zhang H, et al. The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genomics. 2014;24(4):204–10.
    • (2014) Pharmacogenet Genomics. , vol.24 , Issue.4 , pp. 204-210
    • Xie, C.1    Ding, X.2    Gao, J.3    Wang, H.4    Hang, Y.5    Zhang, H.6
  • 71
    • 84894040619 scopus 로고    scopus 로고
    • CES1A—816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BC2cXitFWmu7w%3D, PID: 24508947
    • Zou JJ, Chen SL, Fan HW, Tan J, He BS, Xie HG. CES1A—816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. J Cardiovasc Pharmacol. 2014;63(2):178–83.
    • (2014) J Cardiovasc Pharmacol. , vol.63 , Issue.2 , pp. 178-183
    • Zou, J.J.1    Chen, S.L.2    Fan, H.W.3    Tan, J.4    He, B.S.5    Xie, H.G.6
  • 72
    • 84881126177 scopus 로고    scopus 로고
    • Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes
    • COI: 1:CAS:528:DC%2BC38Xlt1Klsro%3D, PID: 22491019
    • Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J. 2013;13(4):369–77.
    • (2013) Pharmacogenomics J. , vol.13 , Issue.4 , pp. 369-377
    • Martis, S.1    Peter, I.2    Hulot, J.S.3    Kornreich, R.4    Desnick, R.J.5    Scott, S.A.6
  • 73
    • 0036394942 scopus 로고    scopus 로고
    • Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    • COI: 1:CAS:528:DC%2BD38XotlGisbg%3D, PID: 12222994
    • Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–58.
    • (2002) Clin Pharmacokinet. , vol.41 , Issue.12 , pp. 913-958
    • Desta, Z.1    Zhao, X.2    Shin, J.G.3    Flockhart, D.A.4
  • 74
    • 78049433100 scopus 로고    scopus 로고
    • Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    • COI: 1:CAS:528:DC%2BC3cXhtlKitL%2FP, PID: 20979470
    • Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704–14.
    • (2010) N Engl J Med. , vol.363 , Issue.18 , pp. 1704-1714
    • Pare, G.1    Mehta, S.R.2    Yusuf, S.3    Anand, S.S.4    Connolly, S.J.5    Hirsh, J.6
  • 75
    • 36348943475 scopus 로고    scopus 로고
    • Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    • COI: 1:CAS:528:DC%2BD1cXivFGj, PID: 17900275
    • Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–36.
    • (2007) J Thromb Haemost. , vol.5 , Issue.12 , pp. 2429-2436
    • Brandt, J.T.1    Close, S.L.2    Iturria, S.J.3    Payne, C.D.4    Farid, N.A.5    Ernest, C.S.6
  • 76
    • 84861323788 scopus 로고    scopus 로고
    • Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response
    • COI: 1:CAS:528:DC%2BC38XhslWktrnO, PID: 22374717
    • Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J. 2012;33(22):2856–64.
    • (2012) Eur Heart J. , vol.33 , Issue.22 , pp. 2856-2864
    • Gong, I.Y.1    Crown, N.2    Suen, C.M.3    Schwarz, U.I.4    Dresser, G.K.5    Knauer, M.J.6
  • 77
    • 84880875455 scopus 로고    scopus 로고
    • The CYP2C19*17 variant is not independently associated with clopidogrel response
    • COI: 1:CAS:528:DC%2BC3sXhsVKgsr3L, PID: 23809542
    • Lewis J, Stephens S, Horenstein R, O’Connell J, Ryan K, Peer C, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013;11(9):1640–6.
    • (2013) J Thromb Haemost. , vol.11 , Issue.9 , pp. 1640-1646
    • Lewis, J.1    Stephens, S.2    Horenstein, R.3    O’Connell, J.4    Ryan, K.5    Peer, C.6
  • 78
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    • COI: 1:CAS:528:DC%2BD1MXhtVaqtrY%3D, PID: 19108880
    • Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–17.
    • (2009) Lancet. , vol.373 , Issue.9660 , pp. 309-317
    • Collet, J.P.1    Hulot, J.S.2    Pena, A.3    Villard, E.4    Esteve, J.B.5    Silvain, J.6
  • 79
    • 82955240702 scopus 로고    scopus 로고
    • CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    • COI: 1:CAS:528:DC%2BC3MXhs1ais7zE, PID: 21972404
    • Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;4(5):422–8.
    • (2011) Circ Cardiovasc Interv. , vol.4 , Issue.5 , pp. 422-428
    • Hulot, J.S.1    Collet, J.P.2    Cayla, G.3    Silvain, J.4    Allanic, F.5    Bellemain-Appaix, A.6
  • 80
    • 79960603688 scopus 로고    scopus 로고
    • Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects
    • COI: 1:CAS:528:DC%2BC3MXptVOnurY%3D, PID: 21716274
    • Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011;90(2):287–95.
    • (2011) Clin Pharmacol Ther. , vol.90 , Issue.2 , pp. 287-295
    • Simon, T.1    Bhatt, D.L.2    Bergougnan, L.3    Farenc, C.4    Pearson, K.5    Perrin, L.6
  • 81
    • 38449103046 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+ 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
    • COI: 1:CAS:528:DC%2BD2sXhsVWiu7%2FK, PID: 18004210
    • Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+ 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057–64.
    • (2007) Pharmacogenet Genomics. , vol.17 , Issue.12 , pp. 1057-1064
    • Giusti, B.1    Gori, A.M.2    Marcucci, R.3    Saracini, C.4    Sestini, I.5    Paniccia, R.6
  • 82
    • 79960012663 scopus 로고    scopus 로고
    • No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
    • COI: 1:CAS:528:DC%2BC3MXos1Smtr8%3D, PID: 21527445
    • Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32(13):1605–13.
    • (2011) Eur Heart J. , vol.32 , Issue.13 , pp. 1605-1613
    • Sibbing, D.1    Koch, W.2    Massberg, S.3    Byrne, R.A.4    Mehilli, J.5    Schulz, S.6
  • 83
    • 84155167902 scopus 로고    scopus 로고
    • Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
    • COI: 1:CAS:528:DC%2BC38XivVaksbc%3D, PID: 21693476
    • Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–8.
    • (2012) Heart. , vol.98 , Issue.2 , pp. 100-108
    • Zabalza, M.1    Subirana, I.2    Sala, J.3    Lluis-Ganella, C.4    Lucas, G.5    Tomas, M.6
  • 84
    • 84883184552 scopus 로고    scopus 로고
    • Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics
    • COI: 1:CAS:528:DC%2BC3sXhtlSju7nN, PID: 23670120
    • Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther. 2013;94(3):376–82.
    • (2013) Clin Pharmacol Ther. , vol.94 , Issue.3 , pp. 376-382
    • Sorich, M.J.1    Polasek, T.M.2    Wiese, M.D.3
  • 85
    • 78049326068 scopus 로고    scopus 로고
    • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    • COI: 1:CAS:528:DC%2BC3cXhtlGqurbO, PID: 20978260
    • Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30.
    • (2010) JAMA. , vol.304 , Issue.16 , pp. 1821-1830
    • Mega, J.L.1    Simon, T.2    Collet, J.P.3    Anderson, J.L.4    Antman, E.M.5    Bliden, K.6
  • 86
    • 79952435294 scopus 로고    scopus 로고
    • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
    • COI: 1:CAS:528:DC%2BC3MXjtFWitb4%3D, PID: 21392617
    • Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161(3):598–604.
    • (2011) Am Heart J. , vol.161 , Issue.3 , pp. 598-604
    • Gurbel, P.A.1    Shuldiner, A.R.2    Bliden, K.P.3    Ryan, K.4    Pakyz, R.E.5    Tantry, U.S.6
  • 87
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • COI: 1:CAS:528:DC%2BC3cXpsVensg%3D%3D, PID: 20083681
    • Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–8.
    • (2010) Circulation. , vol.121 , Issue.4 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3    Schuster, T.4    Braun, S.5    Stegherr, J.6
  • 88
    • 84864348920 scopus 로고    scopus 로고
    • Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness
    • COI: 1:CAS:528:DC%2BC3MXisFKlurs%3D, PID: 21358751
    • Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J. 2012;12(4):297–305.
    • (2012) Pharmacogenomics J. , vol.12 , Issue.4 , pp. 297-305
    • Scott, S.A.1    Martis, S.2    Peter, I.3    Kasai, Y.4    Kornreich, R.5    Desnick, R.J.6
  • 89
    • 80054782748 scopus 로고    scopus 로고
    • Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme
    • COI: 1:CAS:528:DC%2BC3MXhs1ektb3N, PID: 21862689
    • Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol Pharmacol. 2011;80(5):839–47.
    • (2011) Mol Pharmacol. , vol.80 , Issue.5 , pp. 839-847
    • Zhang, H.1    Amunugama, H.2    Ney, S.3    Cooper, N.4    Hollenberg, P.F.5
  • 90
    • 61449129603 scopus 로고    scopus 로고
    • Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel
    • COI: 1:CAS:528:DC%2BD1MXislamtLY%3D, PID: 19047469
    • Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, et al. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos. 2009;37(3):589–93.
    • (2009) Drug Metab Dispos. , vol.37 , Issue.3 , pp. 589-593
    • Nishiya, Y.1    Hagihara, K.2    Ito, T.3    Tajima, M.4    Miura, S.5    Kurihara, A.6
  • 91
    • 20444458419 scopus 로고    scopus 로고
    • Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation
    • COI: 1:CAS:528:DC%2BD2MXlt1Gqt7k%3D, PID: 15961986
    • Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553–9.
    • (2005) Clin Pharmacol Ther. , vol.77 , Issue.6 , pp. 553-559
    • Turpeinen, M.1    Tolonen, A.2    Uusitalo, J.3    Jalonen, J.4    Pelkonen, O.5    Laine, K.6
  • 92
    • 33746792912 scopus 로고    scopus 로고
    • Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
    • COI: 1:CAS:528:DC%2BD28XmvFaks7w%3D, PID: 16645157
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26(8):1895–900.
    • (2006) Arterioscler Thromb Vasc Biol. , vol.26 , Issue.8 , pp. 1895-1900
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Ramirez, C.4    Cavallari, U.5    Trabetti, E.6
  • 93
    • 33744968214 scopus 로고    scopus 로고
    • Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
    • PID: 16754899
    • Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174(12):1715–22.
    • (2006) CMAJ. , vol.174 , Issue.12 , pp. 1715-1722
    • Suh, J.W.1    Koo, B.K.2    Zhang, S.Y.3    Park, K.W.4    Cho, J.Y.5    Jang, I.J.6
  • 94
    • 84865198262 scopus 로고    scopus 로고
    • Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BC38Xhs1KmsbvI, PID: 22735685
    • Park KW, Kang J, Park JJ, Yang HM, Lee HY, Kang HJ, et al. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart. 2012;98(18):1366–72.
    • (2012) Heart. , vol.98 , Issue.18 , pp. 1366-1372
    • Park, K.W.1    Kang, J.2    Park, J.J.3    Yang, H.M.4    Lee, H.Y.5    Kang, H.J.6
  • 95
    • 40949127806 scopus 로고    scopus 로고
    • Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk
    • COI: 1:CAS:528:DC%2BD1cXjsVOmtb8%3D, PID: 18349088
    • Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299(11):1265–76.
    • (2008) JAMA. , vol.299 , Issue.11 , pp. 1265-1276
    • Bhattacharyya, T.1    Nicholls, S.J.2    Topol, E.J.3    Zhang, R.4    Yang, X.5    Schmitt, D.6
  • 96
    • 84873919772 scopus 로고    scopus 로고
    • Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI
    • COI: 1:CAS:528:DC%2BC3sXjtlCmtLk%3D, PID: 23418418
    • Park KW, Park JJ, Kang J, Jeon KH, Kang SH, Han JK, et al. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI. PLoS One. 2013;8(2):e52779.
    • (2013) PLoS One. , vol.8 , Issue.2 , pp. e52779
    • Park, K.W.1    Park, J.J.2    Kang, J.3    Jeon, K.H.4    Kang, S.H.5    Han, J.K.6
  • 97
    • 84863500468 scopus 로고    scopus 로고
    • Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis
    • COI: 1:CAS:528:DC%2BC38Xht1ChtbfL, PID: 22520065
    • Reny JL, Combescure C, Daali Y, Fontana P, Group PONM-A. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost. 2012;10(7):1242–51.
    • (2012) J Thromb Haemost. , vol.10 , Issue.7 , pp. 1242-1251
    • Reny, J.L.1    Combescure, C.2    Daali, Y.3    Fontana, P.4    Group PONM-A5
  • 98
    • 84880514104 scopus 로고    scopus 로고
    • Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients
    • COI: 1:CAS:528:DC%2BC3sXhtFenu77F, PID: 23608957
    • Kang YH, Lao HY, Wu H, Lai WH, Li XX, Yu XY, et al. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol. 2013;69(8):1511–9.
    • (2013) Eur J Clin Pharmacol. , vol.69 , Issue.8 , pp. 1511-1519
    • Kang, Y.H.1    Lao, H.Y.2    Wu, H.3    Lai, W.H.4    Li, X.X.5    Yu, X.Y.6
  • 99
    • 35748969344 scopus 로고    scopus 로고
    • Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease
    • PID: 17803810
    • Cavallari U, Trabetti E, Malerba G, Biscuola M, Girelli D, Olivieri O, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet. 2007;8:59.
    • (2007) BMC Med Genet. , vol.8 , pp. 59
    • Cavallari, U.1    Trabetti, E.2    Malerba, G.3    Biscuola, M.4    Girelli, D.5    Olivieri, O.6
  • 100
    • 0042859862 scopus 로고    scopus 로고
    • Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
    • COI: 1:CAS:528:DC%2BD3sXmsVOrs7c%3D, PID: 12912815
    • Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108(8):989–95.
    • (2003) Circulation. , vol.108 , Issue.8 , pp. 989-995
    • Fontana, P.1    Dupont, A.2    Gandrille, S.3    Bachelot-Loza, C.4    Reny, J.L.5    Aiach, M.6
  • 101
    • 63149100441 scopus 로고    scopus 로고
    • Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene
    • PID: 18485500
    • Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009;133(3):341–5.
    • (2009) Int J Cardiol. , vol.133 , Issue.3 , pp. 341-345
    • Staritz, P.1    Kurz, K.2    Stoll, M.3    Giannitsis, E.4    Katus, H.A.5    Ivandic, B.T.6
  • 102
    • 24944465039 scopus 로고    scopus 로고
    • Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease
    • COI: 1:CAS:528:DC%2BD2MXhtVegtLbM, PID: 16181985
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005;116(6):491–7.
    • (2005) Thromb Res. , vol.116 , Issue.6 , pp. 491-497
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Ramirez, C.4    Cavallari, U.5    Trabetti, E.6
  • 103
    • 34548722718 scopus 로고    scopus 로고
    • Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome
    • COI: 1:CAS:528:DC%2BD2sXhtVOgs7%2FK, PID: 17337040
    • Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Lambert M, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res. 2007;120(6):893–9.
    • (2007) Thromb Res. , vol.120 , Issue.6 , pp. 893-899
    • Cuisset, T.1    Frere, C.2    Quilici, J.3    Morange, P.E.4    Saut, N.5    Lambert, M.6
  • 104
    • 80054919425 scopus 로고    scopus 로고
    • Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
    • COI: 1:CAS:528:DC%2BC3MXhtl2ktr3L, PID: 22028352
    • Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765–74.
    • (2011) JAMA. , vol.306 , Issue.16 , pp. 1765-1774
    • Cayla, G.1    Hulot, J.S.2    O’Connor, S.A.3    Pathak, A.4    Scott, S.A.5    Gruel, Y.6
  • 105
    • 40549106434 scopus 로고    scopus 로고
    • Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions
    • COI: 1:CAS:528:DC%2BD1cXktlahsbw%3D, PID: 18175333
    • Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, Zwinderman A, et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat. 2008;29(3):375–80.
    • (2008) Hum Mutat. , vol.29 , Issue.3 , pp. 375-380
    • Rudez, G.1    Pons, D.2    Leebeek, F.3    Monraats, P.4    Schrevel, M.5    Zwinderman, A.6
  • 106
    • 22044450322 scopus 로고    scopus 로고
    • Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease
    • COI: 1:CAS:528:DC%2BD2MXlsVyjtro%3D, PID: 15933261
    • Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005;36(7):1394–9.
    • (2005) Stroke. , vol.36 , Issue.7 , pp. 1394-1399
    • Ziegler, S.1    Schillinger, M.2    Funk, M.3    Felber, K.4    Exner, M.5    Mlekusch, W.6
  • 107
    • 84876923072 scopus 로고    scopus 로고
    • Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention
    • COI: 1:CAS:528:DC%2BC3sXpsVCmurs%3D, PID: 23506580
    • Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J. 2013;126(6):1069–75.
    • (2013) Chin Med J. , vol.126 , Issue.6 , pp. 1069-1075
    • Tang, X.F.1    Zhang, J.H.2    Wang, J.3    Han, Y.L.4    Xu, B.5    Qiao, S.B.6
  • 108
    • 77949907998 scopus 로고    scopus 로고
    • Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions
    • COI: 1:CAS:528:DC%2BD1MXhsVCksbzK, PID: 20031628
    • Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet. 2009;2(5):515–21.
    • (2009) Circ Cardiovasc Genet. , vol.2 , Issue.5 , pp. 515-521
    • Rudez, G.1    Bouman, H.J.2    van Werkum, J.W.3    Leebeek, F.W.4    Kruit, A.5    Ruven, H.J.6
  • 109
    • 84855302301 scopus 로고    scopus 로고
    • The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up
    • COI: 1:CAS:528:DC%2BC38XitVKnu74%3D, PID: 22159428
    • Bouman HJ, van Werkum JW, Rudez G, Hackeng CM, Leebeek FW, ten Cate H, et al. The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. Thromb Haemost. 2012;107(1):189–91.
    • (2012) Thromb Haemost. , vol.107 , Issue.1 , pp. 189-191
    • Bouman, H.J.1    van Werkum, J.W.2    Rudez, G.3    Hackeng, C.M.4    Leebeek, F.W.5    ten Cate, H.6
  • 110
    • 11144357704 scopus 로고    scopus 로고
    • PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation
    • PID: 15166949
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15(1):89–93.
    • (2004) Blood Coagul Fibrinolysis. , vol.15 , Issue.1 , pp. 89-93
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Alfonso, F.4    Sabate, M.5    Fernandez, C.6
  • 111
    • 33845490833 scopus 로고    scopus 로고
    • Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel
    • COI: 1:CAS:528:DC%2BD2sXhslyqtQ%3D%3D, PID: 16581111
    • Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007;119(3):355–60.
    • (2007) Thromb Res. , vol.119 , Issue.3 , pp. 355-360
    • Lev, E.I.1    Patel, R.T.2    Guthikonda, S.3    Lopez, D.4    Bray, P.F.5    Kleiman, N.S.6
  • 112
    • 33644972034 scopus 로고    scopus 로고
    • P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel
    • COI: 1:CAS:528:DC%2BD28XjvFeqsrc%3D, PID: 16634769
    • Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. J Thromb Haemost. 2006;4(4):912–4.
    • (2006) J Thromb Haemost. , vol.4 , Issue.4 , pp. 912-914
    • Sibbing, D.1    von Beckerath, O.2    Schomig, A.3    Kastrati, A.4    von Beckerath, N.5
  • 113
    • 49949090275 scopus 로고    scopus 로고
    • The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies
    • COI: 1:CAS:528:DC%2BD1cXhtVShtr%2FP, PID: 18615002
    • Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417–23.
    • (2008) Clin Pharmacol Ther. , vol.84 , Issue.3 , pp. 417-423
    • Yasuda, S.U.1    Zhang, L.2    Huang, S.M.3
  • 114
    • 77952927473 scopus 로고    scopus 로고
    • Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    • COI: 1:CAS:528:DC%2BC3cXmsFSnt7g%3D, PID: 20504253
    • Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11(6):781–91.
    • (2010) Pharmacogenomics. , vol.11 , Issue.6 , pp. 781-791
    • Scott, S.A.1    Khasawneh, R.2    Peter, I.3    Kornreich, R.4    Desnick, R.J.5
  • 115
    • 3042772026 scopus 로고    scopus 로고
    • Identification of functionally variant MDR1 alleles among European Americans and African Americans
    • COI: 1:CAS:528:DC%2BD3MXmslygs7o%3D, PID: 11503014
    • Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99.
    • (2001) Clin Pharmacol Ther. , vol.70 , Issue.2 , pp. 189-199
    • Kim, R.B.1    Leake, B.F.2    Choo, E.F.3    Dresser, G.K.4    Kubba, S.V.5    Schwarz, U.I.6
  • 116
    • 84873909989 scopus 로고    scopus 로고
    • Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention
    • COI: 1:CAS:528:DC%2BC3sXivVGgs78%3D, PID: 23110469
    • Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123(3):143–54.
    • (2013) Int J Neurosci. , vol.123 , Issue.3 , pp. 143-154
    • Hasan, M.S.1    Basri, H.B.2    Hin, L.P.3    Stanslas, J.4
  • 117
    • 84857632980 scopus 로고    scopus 로고
    • Clopidogrel and PPI interaction: clinically relevant or not?
    • PID: 22090195
    • Harrison RW, Mahaffey KW. Clopidogrel and PPI interaction: clinically relevant or not? Curr Cardiol Rep. 2012;14(1):49–58.
    • (2012) Curr Cardiol Rep. , vol.14 , Issue.1 , pp. 49-58
    • Harrison, R.W.1    Mahaffey, K.W.2
  • 118
    • 78649823909 scopus 로고    scopus 로고
    • ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
    • PID: 21131924
    • Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.
    • (2010) Am J Gastroenterol. , vol.105 , Issue.12 , pp. 2533-2549
    • Abraham, N.S.1    Hlatky, M.A.2    Antman, E.M.3    Bhatt, D.L.4    Bjorkman, D.J.5    Clark, C.B.6
  • 119
    • 84861891333 scopus 로고    scopus 로고
    • Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4
    • COI: 1:CAS:528:DC%2BC38XnslKntr4%3D, PID: 22313038
    • Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012;42(7):633–40.
    • (2012) Xenobiotica. , vol.42 , Issue.7 , pp. 633-640
    • Ohbuchi, M.1    Noguchi, K.2    Kawamura, A.3    Usui, T.4
  • 120
    • 78650517232 scopus 로고    scopus 로고
    • Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies
    • COI: 1:CAS:528:DC%2BC3cXhsFylt7zP, PID: 20844485
    • Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65–74.
    • (2011) Clin Pharmacol Ther. , vol.89 , Issue.1 , pp. 65-74
    • Angiolillo, D.J.1    Gibson, C.M.2    Cheng, S.3    Ollier, C.4    Nicolas, O.5    Bergougnan, L.6
  • 121
    • 84859138447 scopus 로고    scopus 로고
    • A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    • COI: 1:CAS:528:DC%2BC38XltVKiu7w%3D, PID: 22464259
    • Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–11.
    • (2012) J Am Coll Cardiol. , vol.59 , Issue.14 , pp. 1304-1311
    • Frelinger, A.L.1    Lee, R.D.2    Mulford, D.J.3    Wu, J.4    Nudurupati, S.5    Nigam, A.6
  • 122
    • 79955057805 scopus 로고    scopus 로고
    • Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel–PPIs drug interaction
    • COI: 1:CAS:528:DC%2BC3MXks1Whs74%3D, PID: 21464720
    • Fontes-Carvalho R, Albuquerque A, Araujo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel–PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396–404.
    • (2011) Eur J Gastroenterol Hepatol. , vol.23 , Issue.5 , pp. 396-404
    • Fontes-Carvalho, R.1    Albuquerque, A.2    Araujo, C.3    Pimentel-Nunes, P.4    Ribeiro, V.G.5
  • 123
    • 77955718769 scopus 로고    scopus 로고
    • Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes
    • COI: 1:CAS:528:DC%2BC3cXhtFOkurrK, PID: 20716239
    • Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383–92.
    • (2010) Br J Clin Pharmacol. , vol.70 , Issue.3 , pp. 383-392
    • Furuta, T.1    Iwaki, T.2    Umemura, K.3
  • 124
    • 40749094082 scopus 로고    scopus 로고
    • Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    • COI: 1:CAS:528:DC%2BD1cXkslKntLk%3D, PID: 18303127
    • Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–84.
    • (2008) J Clin Pharmacol. , vol.48 , Issue.4 , pp. 475-484
    • Small, D.S.1    Farid, N.A.2    Payne, C.D.3    Weerakkody, G.J.4    Li, Y.G.5    Brandt, J.T.6
  • 125
    • 77949290490 scopus 로고    scopus 로고
    • Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects
    • COI: 1:CAS:528:DC%2BC3cXktF2hsb4%3D, PID: 20040040
    • Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, et al. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost. 2010;8(3):610–3.
    • (2010) J Thromb Haemost. , vol.8 , Issue.3 , pp. 610-613
    • Hulot, J.S.1    Wuerzner, G.2    Bachelot-Loza, C.3    Azizi, M.4    Blanchard, A.5    Peyrard, S.6
  • 126
    • 84925514861 scopus 로고    scopus 로고
    • US Food and Drug Administration (FDA). Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert heal.thcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. Accessed 12 Sept 2014
    • US Food and Drug Administration (FDA). Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert heal.thcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed 12 Sept 2014.
  • 127
    • 84925514860 scopus 로고    scopus 로고
    • US Food and Drug Administration (FDA). Plavix (clopidogrel bisulfate) tablets labeling revision. 2011. Accessed 4 Aug 2013
    • US Food and Drug Administration (FDA). Plavix (clopidogrel bisulfate) tablets labeling revision. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020839s055lbl.pdf. Accessed 4 Aug 2013.
  • 128
    • 78149487926 scopus 로고    scopus 로고
    • Clopidogrel with or without omeprazole in coronary artery disease
    • COI: 1:CAS:528:DC%2BC3cXhsVCht7rN, PID: 20925534
    • Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.
    • (2010) N Engl J Med. , vol.363 , Issue.20 , pp. 1909-1917
    • Bhatt, D.L.1    Cryer, B.L.2    Contant, C.F.3    Cohen, M.4    Lanas, A.5    Schnitzer, T.J.6
  • 129
    • 61549124132 scopus 로고    scopus 로고
    • Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
    • COI: 1:CAS:528:DC%2BD1MXivFejt7g%3D, PID: 19258584
    • Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–44.
    • (2009) JAMA. , vol.301 , Issue.9 , pp. 937-944
    • Ho, P.M.1    Maddox, T.M.2    Wang, L.3    Fihn, S.D.4    Jesse, R.L.5    Peterson, E.D.6
  • 130
    • 84875242008 scopus 로고    scopus 로고
    • Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review
    • PID: 22851683
    • Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart. 2013;99(8):520–7.
    • (2013) Heart. , vol.99 , Issue.8 , pp. 520-527
    • Focks, J.J.1    Brouwer, M.A.2    van Oijen, M.G.3    Lanas, A.4    Bhatt, D.L.5    Verheugt, F.W.6
  • 131
    • 78349244351 scopus 로고    scopus 로고
    • Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis
    • COI: 1:STN:280:DC%2BC3M%2FitlGlug%3D%3D, PID: 20831618
    • Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–41.
    • (2010) J Thromb Haemost. , vol.8 , Issue.12 , pp. 2624-2641
    • Siller-Matula, J.M.1    Jilma, B.2    Schror, K.3    Christ, G.4    Huber, K.5
  • 132
    • 84863631246 scopus 로고    scopus 로고
    • Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature
    • COI: 1:CAS:528:DC%2BC38XmtVemu7k%3D, PID: 22198703
    • Gerson LB, McMahon D, Olkin I, Stave C, Rockson SG. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci. 2012;57(5):1304–13.
    • (2012) Dig Dis Sci. , vol.57 , Issue.5 , pp. 1304-1313
    • Gerson, L.B.1    McMahon, D.2    Olkin, I.3    Stave, C.4    Rockson, S.G.5
  • 133
    • 77955989559 scopus 로고    scopus 로고
    • Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography–tandem mass spectrometry cocktail assay in human hepatocytes
    • COI: 1:CAS:528:DC%2BC3cXhtFegu7rO, PID: 20551241
    • Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, et al. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography–tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos. 2010;38(9):1589–97.
    • (2010) Drug Metab Dispos. , vol.38 , Issue.9 , pp. 1589-1597
    • Feidt, D.M.1    Klein, K.2    Hofmann, U.3    Riedmaier, S.4    Knobeloch, D.5    Thasler, W.E.6
  • 134
    • 79958820071 scopus 로고    scopus 로고
    • The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes
    • COI: 1:CAS:528:DC%2BC3MXntlOlu7c%3D, PID: 21476904
    • Howe K, Sanat F, Thumser AE, Coleman T, Plant N. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica. 2011;41(7):519–29.
    • (2011) Xenobiotica. , vol.41 , Issue.7 , pp. 519-529
    • Howe, K.1    Sanat, F.2    Thumser, A.E.3    Coleman, T.4    Plant, N.5
  • 135
    • 57149084688 scopus 로고    scopus 로고
    • Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    • COI: 1:CAS:528:DC%2BD1MXjvVKkug%3D%3D, PID: 19025429
    • Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28(12):1483–94.
    • (2008) Pharmacotherapy. , vol.28 , Issue.12 , pp. 1483-1494
    • Farid, N.A.1    Small, D.S.2    Payne, C.D.3    Jakubowski, J.A.4    Brandt, J.T.5    Li, Y.G.6
  • 136
    • 84899945598 scopus 로고    scopus 로고
    • Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status
    • COI: 1:CAS:528:DC%2BC2cXmvVWis7g%3D, PID: 23852152
    • Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, et al. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. J Thromb Thrombolysis. 2014;37(4):427–34.
    • (2014) J Thromb Thrombolysis. , vol.37 , Issue.4 , pp. 427-434
    • Leoncini, M.1    Toso, A.2    Maioli, M.3    Angiolillo, D.J.4    Giusti, B.5    Marcucci, R.6
  • 137
    • 0242298647 scopus 로고    scopus 로고
    • Effects of statins on platelet inhibition by a high loading dose of clopidogrel
    • PID: 14568892
    • Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 2003;108(18):2195–7.
    • (2003) Circulation. , vol.108 , Issue.18 , pp. 2195-2197
    • Muller, I.1    Besta, F.2    Schulz, C.3    Li, Z.4    Massberg, S.5    Gawaz, M.6
  • 138
    • 6344226832 scopus 로고    scopus 로고
    • Absence of interaction between atorvastatin or other statins and clopidogrel: results from the Interaction Study
    • COI: 1:CAS:528:DC%2BD2cXptl2ktrg%3D, PID: 15477442
    • Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the Interaction Study. Arch Intern Med. 2004;164(18):2051–7.
    • (2004) Arch Intern Med. , vol.164 , Issue.18 , pp. 2051-2057
    • Serebruany, V.L.1    Midei, M.G.2    Malinin, A.I.3    Oshrine, B.R.4    Lowry, D.R.5    Sane, D.C.6
  • 139
    • 10644287731 scopus 로고    scopus 로고
    • Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BD2cXhtVarsrvI, PID: 15763887
    • Smith SM, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets. 2004;15(8):465–74.
    • (2004) Platelets. , vol.15 , Issue.8 , pp. 465-474
    • Smith, S.M.1    Judge, H.M.2    Peters, G.3    Storey, R.F.4
  • 140
    • 38349168982 scopus 로고    scopus 로고
    • Impact of cytochrome P450 3A4–metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement
    • COI: 1:CAS:528:DC%2BD1cXhtlWisrY%3D, PID: 18217151
    • Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, et al. Impact of cytochrome P450 3A4–metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008;99(1):174–81.
    • (2008) Thromb Haemost. , vol.99 , Issue.1 , pp. 174-181
    • Trenk, D.1    Hochholzer, W.2    Frundi, D.3    Stratz, C.4    Valina, C.M.5    Bestehorn, H.P.6
  • 141
    • 55449137355 scopus 로고    scopus 로고
    • CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
    • COI: 1:CAS:528:DC%2BD1cXhtV2mtbnP, PID: 18781853
    • Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9(9):1251–9.
    • (2008) Pharmacogenomics. , vol.9 , Issue.9 , pp. 1251-1259
    • Geisler, T.1    Schaeffeler, E.2    Dippon, J.3    Winter, S.4    Buse, V.5    Bischofs, C.6
  • 142
    • 70349887593 scopus 로고    scopus 로고
    • Influence of statin treatment on platelet inhibition by clopidogrel—a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment
    • PID: 19549094
    • Malmstrom RE, Ostergren J, Jorgensen L, Hjemdahl P. Influence of statin treatment on platelet inhibition by clopidogrel—a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med. 2009;266(5):457–66.
    • (2009) J Intern Med. , vol.266 , Issue.5 , pp. 457-466
    • Malmstrom, R.E.1    Ostergren, J.2    Jorgensen, L.3    Hjemdahl, P.4
  • 143
    • 77956623528 scopus 로고    scopus 로고
    • A randomised determination of the effect of fluvastatin and atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial
    • COI: 1:CAS:528:DC%2BC3cXht1Onsr7J, PID: 20664903
    • Wenaweser P, Eshtehardi P, Abrecht L, Zwahlen M, Schmidlin K, Windecker S, et al. A randomised determination of the effect of fluvastatin and atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost. 2010;104(3):554–62.
    • (2010) Thromb Haemost. , vol.104 , Issue.3 , pp. 554-562
    • Wenaweser, P.1    Eshtehardi, P.2    Abrecht, L.3    Zwahlen, M.4    Schmidlin, K.5    Windecker, S.6
  • 144
    • 67650901939 scopus 로고    scopus 로고
    • Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin’s advantage and the smoking “paradox
    • COI: 1:CAS:528:DC%2BD1MXmtVOnsr8%3D, PID: 19247187
    • Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin’s advantage and the smoking “paradox”. J Cardiovasc Pharmacol. 2009;53(5):368–72.
    • (2009) J Cardiovasc Pharmacol. , vol.53 , Issue.5 , pp. 368-372
    • Motovska, Z.1    Widimsky, P.2    Petr, R.3    Bilkova, D.4    Marinov, I.5    Simek, S.6
  • 145
    • 33846445325 scopus 로고    scopus 로고
    • Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis
    • COI: 1:CAS:528:DC%2BD2sXhtVKgtLk%3D, PID: 17261397
    • Wenaweser P, Windecker S, Billinger M, Cook S, Togni M, Meier B, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol. 2007;99(3):353–6.
    • (2007) Am J Cardiol. , vol.99 , Issue.3 , pp. 353-356
    • Wenaweser, P.1    Windecker, S.2    Billinger, M.3    Cook, S.4    Togni, M.5    Meier, B.6
  • 146
    • 0042848535 scopus 로고    scopus 로고
    • Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies
    • COI: 1:CAS:528:DC%2BD3sXlvVWitr4%3D, PID: 12888133
    • Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol. 2003;92(3):285–8.
    • (2003) Am J Cardiol. , vol.92 , Issue.3 , pp. 285-288
    • Wienbergen, H.1    Gitt, A.K.2    Schiele, R.3    Juenger, C.4    Heer, T.5    Meisenzahl, C.6
  • 147
    • 42649083329 scopus 로고    scopus 로고
    • High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis
    • COI: 1:CAS:528:DC%2BD1cXlsFCht7Y%3D, PID: 18440347
    • Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008;155(5):954–8.
    • (2008) Am Heart J. , vol.155 , Issue.5 , pp. 954-958
    • Lotfi, A.1    Schweiger, M.J.2    Giugliano, G.R.3    Murphy, S.A.4    Cannon, C.P.5
  • 148
    • 84875459737 scopus 로고    scopus 로고
    • Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study
    • COI: 1:CAS:528:DC%2BC3sXjvVens7o%3D, PID: 23490041
    • Patti G, Tomai F, Melfi R, Ricottini E, Macri M, Sedati P, et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. J Am Coll Cardiol. 2013;61(13):1379–87.
    • (2013) J Am Coll Cardiol. , vol.61 , Issue.13 , pp. 1379-1387
    • Patti, G.1    Tomai, F.2    Melfi, R.3    Ricottini, E.4    Macri, M.5    Sedati, P.6
  • 149
    • 0034033399 scopus 로고    scopus 로고
    • Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions
    • COI: 1:CAS:528:DC%2BD3cXhslCjs7g%3D, PID: 10805063
    • Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions. Eur J Clin Pharmacol. 2000;55(11–12):843–52.
    • (2000) Eur J Clin Pharmacol. , vol.55 , Issue.11-12 , pp. 843-852
    • Katoh, M.1    Nakajima, M.2    Shimada, N.3    Yamazaki, H.4    Yokoi, T.5
  • 150
    • 54349121974 scopus 로고    scopus 로고
    • Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    • COI: 1:CAS:528:DC%2BD1cXhtlahtbnI, PID: 19007592
    • Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52(19):1557–63.
    • (2008) J Am Coll Cardiol. , vol.52 , Issue.19 , pp. 1557-1563
    • Siller-Matula, J.M.1    Lang, I.2    Christ, G.3    Jilma, B.4
  • 151
    • 79952444959 scopus 로고    scopus 로고
    • Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
    • COI: 1:CAS:528:DC%2BC3MXjtFWitb8%3D, PID: 21392618
    • Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J. 2011;161(3):605–10.
    • (2011) Am Heart J. , vol.161 , Issue.3 , pp. 605-610
    • Sarafoff, N.1    Neumann, L.2    Morath, T.3    Bernlochner, I.4    Mehilli, J.5    Schomig, A.6
  • 152
    • 84856581921 scopus 로고    scopus 로고
    • Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events
    • COI: 1:CAS:528:DC%2BC38XkvFyisr0%3D, PID: 21834799
    • Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. Eur J Clin Invest. 2012;42(3):266–74.
    • (2012) Eur J Clin Invest. , vol.42 , Issue.3 , pp. 266-274
    • Schmidt, M.1    Johansen, M.B.2    Robertson, D.J.3    Maeng, M.4    Kaltoft, A.5    Jensen, L.O.6
  • 153
    • 84860864875 scopus 로고    scopus 로고
    • Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    • COI: 1:CAS:528:DC%2BC38XnvVKnsbs%3D, PID: 22319066
    • Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv. 2012;5(1):77–81.
    • (2012) Circ Cardiovasc Interv. , vol.5 , Issue.1 , pp. 77-81
    • Good, C.W.1    Steinhubl, S.R.2    Brennan, D.M.3    Lincoff, A.M.4    Topol, E.J.5    Berger, P.B.6
  • 154
    • 80053419318 scopus 로고    scopus 로고
    • Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BC3MXhsV2it7fE, PID: 21854540
    • Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost. 2011;9(10):1892–901.
    • (2011) J Thromb Haemost. , vol.9 , Issue.10 , pp. 1892-1901
    • Harmsze, A.M.1    van Werkum, J.W.2    Souverein, P.C.3    Breet, N.J.4    Bouman, H.J.5    Hackeng, C.M.6
  • 155
    • 79751504243 scopus 로고    scopus 로고
    • Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients
    • COI: 1:CAS:528:DC%2BC3MXhsFyjur8%3D, PID: 21142408
    • Harmsze AM, Van Werkum JW, Moral F, Ten Berg JN, Hackeng CM, Klungel OH, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets. 2011;22(2):98–102.
    • (2011) Platelets. , vol.22 , Issue.2 , pp. 98-102
    • Harmsze, A.M.1    Van Werkum, J.W.2    Moral, F.3    Ten Berg, J.N.4    Hackeng, C.M.5    Klungel, O.H.6
  • 156
    • 77952400164 scopus 로고    scopus 로고
    • Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
    • COI: 1:CAS:528:DC%2BC3cXmtFyrtbo%3D, PID: 20159881
    • Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010;31(10):1205–11.
    • (2010) Eur Heart J. , vol.31 , Issue.10 , pp. 1205-1211
    • Sibbing, D.1    von Beckerath, N.2    Morath, T.3    Stegherr, J.4    Mehilli, J.5    Sarafoff, N.6
  • 157
    • 34247256797 scopus 로고    scopus 로고
    • Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    • COI: 1:CAS:528:DC%2BD2sXlsFCqtro%3D, PID: 17361128
    • Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–41.
    • (2007) Clin Pharmacol Ther. , vol.81 , Issue.5 , pp. 735-741
    • Farid, N.A.1    Payne, C.D.2    Small, D.S.3    Winters, K.J.4    Ernest, C.S.5    Brandt, J.T.6
  • 158
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction
    • COI: 1:CAS:528:DC%2BD3sXhs1M%3D, PID: 12515739
    • Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation. 2003;107(1):32–7.
    • (2003) Circulation. , vol.107 , Issue.1 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3    Neer, C.J.4    Horowitz, K.5    Hopp, A.S.6
  • 160
    • 79951893032 scopus 로고    scopus 로고
    • Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models
    • COI: 1:CAS:528:DC%2BC3MXks1Kisbs%3D, PID: 20854191
    • Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev. 2011;43(1):27–40.
    • (2011) Drug Metab Rev. , vol.43 , Issue.1 , pp. 27-40
    • Jiang, X.L.1    Gonzalez, F.J.2    Yu, A.M.3
  • 161
    • 78951472564 scopus 로고    scopus 로고
    • The effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity
    • COI: 1:CAS:528:DC%2BC3MXlsFShsA%3D%3D, PID: 20980920
    • Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011;57(1):86–93.
    • (2011) J Cardiovasc Pharmacol. , vol.57 , Issue.1 , pp. 86-93
    • Lau, W.C.1    Welch, T.D.2    Shields, T.3    Rubenfire, M.4    Tantry, U.S.5    Gurbel, P.A.6
  • 162
    • 84858754393 scopus 로고    scopus 로고
    • Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study
    • PID: 22440495
    • Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv. 2012;5(3):293–300.
    • (2012) JACC Cardiovasc Interv. , vol.5 , Issue.3 , pp. 293-300
    • Ueno, M.1    Ferreiro, J.L.2    Desai, B.3    Tomasello, S.D.4    Tello-Montoliu, A.5    Capodanno, D.6
  • 163
    • 84876792488 scopus 로고    scopus 로고
    • Thienopyridine efficacy and cigarette smoking status
    • COI: 1:CAS:528:DC%2BC3sXltVeqtLo%3D, PID: 23622905
    • Bliden KP, Baker BA, Nolin TD, Jeong YH, Bailey WL, Tantry US, et al. Thienopyridine efficacy and cigarette smoking status. Am Heart J. 2013;165(5):693–703.
    • (2013) Am Heart J. , vol.165 , Issue.5 , pp. 693-703
    • Bliden, K.P.1    Baker, B.A.2    Nolin, T.D.3    Jeong, Y.H.4    Bailey, W.L.5    Tantry, U.S.6
  • 164
    • 67650233916 scopus 로고    scopus 로고
    • Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice
    • PID: 19411876
    • James SH. Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice. AACN Adv Crit Care. 2009;20(2):177–92.
    • (2009) AACN Adv Crit Care. , vol.20 , Issue.2 , pp. 177-192
    • James, S.H.1
  • 165
    • 77953189870 scopus 로고    scopus 로고
    • Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    • PID: 20447945
    • Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31(11):1311–8.
    • (2010) Eur Heart J. , vol.31 , Issue.11 , pp. 1311-1318
    • Lip, G.Y.1    Huber, K.2    Andreotti, F.3    Arnesen, H.4    Airaksinen, J.K.5    Cuisset, T.6
  • 166
    • 79952816422 scopus 로고    scopus 로고
    • Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation
    • PID: 21185095
    • Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011;148(1):96–101.
    • (2011) Int J Cardiol. , vol.148 , Issue.1 , pp. 96-101
    • Gao, F.1    Zhou, Y.J.2    Wang, Z.J.3    Yang, S.W.4    Nie, B.5    Liu, X.L.6
  • 167
    • 84878830133 scopus 로고    scopus 로고
    • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    • COI: 1:CAS:528:DC%2BC3sXpsFChsrw%3D, PID: 23470494
    • Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013;34(22):1670–80.
    • (2013) Eur Heart J. , vol.34 , Issue.22 , pp. 1670-1680
    • Oldgren, J.1    Wallentin, L.2    Alexander, J.H.3    James, S.4    Jonelid, B.5    Steg, G.6
  • 168
    • 84875720372 scopus 로고    scopus 로고
    • Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
    • COI: 1:CAS:528:DC%2BC3sXisVOlsLY%3D, PID: 23415013
    • Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.
    • (2013) Lancet. , vol.381 , Issue.9872 , pp. 1107-1115
    • Dewilde, W.J.1    Oirbans, T.2    Verheugt, F.W.3    Kelder, J.C.4    De Smet, B.J.5    Herrman, J.P.6
  • 169
    • 81055122602 scopus 로고    scopus 로고
    • Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction
    • PID: 21948719
    • Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835–43.
    • (2011) CMAJ. , vol.183 , Issue.16 , pp. 1835-1843
    • Labos, C.1    Dasgupta, K.2    Nedjar, H.3    Turecki, G.4    Rahme, E.5
  • 170
    • 84857062139 scopus 로고    scopus 로고
    • Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs
    • COI: 1:CAS:528:DC%2BC3MXhsFGjtrvN, PID: 21893349
    • Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord. 2012;136(1–2):99–103.
    • (2012) J Affect Disord. , vol.136 , Issue.1-2 , pp. 99-103
    • Bismuth-Evenzal, Y.1    Gonopolsky, Y.2    Gurwitz, D.3    Iancu, I.4    Weizman, A.5    Rehavi, M.6
  • 171
    • 0043180436 scopus 로고    scopus 로고
    • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy
    • COI: 1:CAS:528:DC%2BD3sXmsVOrsLo%3D, PID: 12912814
    • Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation. 2003;108(8):939–44.
    • (2003) Circulation. , vol.108 , Issue.8 , pp. 939-944
    • Serebruany, V.L.1    Glassman, A.H.2    Malinin, A.I.3    Nemeroff, C.B.4    Musselman, D.L.5    van Zyl, L.T.6
  • 172
    • 84886598005 scopus 로고    scopus 로고
    • Investigation of drug–drug interactions between clopidogrel and fluoxetine
    • COI: 1:CAS:528:DC%2BC3sXhs1Kktb%2FM, PID: 23413998
    • Delavenne X, Magnin M, Basset T, Piot M, Mallouk N, Ressnikoff D, et al. Investigation of drug–drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol. 2013;27(6):683–9.
    • (2013) Fundam Clin Pharmacol. , vol.27 , Issue.6 , pp. 683-689
    • Delavenne, X.1    Magnin, M.2    Basset, T.3    Piot, M.4    Mallouk, N.5    Ressnikoff, D.6
  • 173
    • 0141593543 scopus 로고    scopus 로고
    • Metabolic drug interactions with new psychotropic agents
    • COI: 1:CAS:528:DC%2BD3sXosVKhs70%3D, PID: 14703714
    • Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17(5):517–38.
    • (2003) Fundam Clin Pharmacol. , vol.17 , Issue.5 , pp. 517-538
    • Spina, E.1    Scordo, M.G.2    D’Arrigo, C.3
  • 174
    • 21744445101 scopus 로고    scopus 로고
    • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction
    • COI: 1:CAS:528:DC%2BD2MXmvVGgt7Y%3D, PID: 15997021
    • Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792–8.
    • (2005) Arch Gen Psychiatry. , vol.62 , Issue.7 , pp. 792-798
    • Taylor, C.B.1    Youngblood, M.E.2    Catellier, D.3    Veith, R.C.4    Carney, R.M.5    Burg, M.M.6
  • 175
    • 84872964429 scopus 로고    scopus 로고
    • Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study
    • COI: 1:CAS:528:DC%2BC3sXhsV2ms74%3D, PID: 23306326
    • Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013;44(2):420–6.
    • (2013) Stroke. , vol.44 , Issue.2 , pp. 420-426
    • Mortensen, J.K.1    Larsson, H.2    Johnsen, S.P.3    Andersen, G.4
  • 176
    • 34248561109 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes
    • COI: 1:CAS:528:DC%2BD2sXlvVaktb8%3D, PID: 17524755
    • Ziegelstein RC, Meuchel J, Kim TJ, Latif M, Alvarez W, Dasgupta N, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med. 2007;120(6):525–30.
    • (2007) Am J Med. , vol.120 , Issue.6 , pp. 525-530
    • Ziegelstein, R.C.1    Meuchel, J.2    Kim, T.J.3    Latif, M.4    Alvarez, W.5    Dasgupta, N.6
  • 177
    • 84867581942 scopus 로고    scopus 로고
    • Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR
    • COI: 1:CAS:528:DC%2BC38XhsVyiu7fK, PID: 22527341
    • Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri H, et al. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol. 2012;68(11):1557–60.
    • (2012) Eur J Clin Pharmacol. , vol.68 , Issue.11 , pp. 1557-1560
    • Maschino, F.1    Hurault-Delarue, C.2    Chebbane, L.3    Fabry, V.4    Montastruc, J.L.5    Bagheri, H.6
  • 178
    • 65449144335 scopus 로고    scopus 로고
    • Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting
    • COI: 1:CAS:528:DC%2BD1MXls12htrY%3D, PID: 19427434
    • Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009;103(10):1391–5.
    • (2009) Am J Cardiol. , vol.103 , Issue.10 , pp. 1391-1395
    • Kim, D.H.1    Daskalakis, C.2    Whellan, D.J.3    Whitman, I.R.4    Hohmann, S.5    Medvedev, S.6
  • 179
    • 23644433510 scopus 로고    scopus 로고
    • Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    • COI: 1:CAS:528:DC%2BD2MXnt1ynt70%3D, PID: 16046311
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430–5.
    • (2005) Diabetes. , vol.54 , Issue.8 , pp. 2430-2435
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3    Ramirez, C.4    Sabate, M.5    Jimenez-Quevedo, P.6
  • 180
    • 79952168736 scopus 로고    scopus 로고
    • Diabetes and antiplatelet therapy in acute coronary syndrome
    • PID: 21343595
    • Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798–813.
    • (2011) Circulation. , vol.123 , Issue.7 , pp. 798-813
    • Ferreiro, J.L.1    Angiolillo, D.J.2
  • 181
    • 79959513241 scopus 로고    scopus 로고
    • Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
    • COI: 1:CAS:528:DC%2BC3MXps1yisLo%3D, PID: 21700086
    • Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2011;58(1):30–9.
    • (2011) J Am Coll Cardiol. , vol.58 , Issue.1 , pp. 30-39
    • Angiolillo, D.J.1    Bernardo, E.2    Zanoni, M.3    Vivas, D.4    Capranzano, P.5    Malerba, G.6
  • 182
    • 56849130022 scopus 로고    scopus 로고
    • Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    • COI: 1:CAS:528:DC%2BD1cXhsVKlsL3M, PID: 19055987
    • Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52(24):1968–77.
    • (2008) J Am Coll Cardiol. , vol.52 , Issue.24 , pp. 1968-1977
    • Erlinge, D.1    Varenhorst, C.2    Braun, O.O.3    James, S.4    Winters, K.J.5    Jakubowski, J.A.6
  • 183
    • 77957681003 scopus 로고    scopus 로고
    • Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
    • COI: 1:CAS:528:DC%2BC3cXhtFyjurrE, PID: 20549497
    • Bogman K, Silkey M, Chan SP, Tomlinson B, Weber C. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. Eur J Clin Pharmacol. 2010;66(10):1005–15.
    • (2010) Eur J Clin Pharmacol. , vol.66 , Issue.10 , pp. 1005-1015
    • Bogman, K.1    Silkey, M.2    Chan, S.P.3    Tomlinson, B.4    Weber, C.5
  • 184
    • 84902554010 scopus 로고    scopus 로고
    • Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients
    • COI: 1:CAS:528:DC%2BC2cXnvFWitLY%3D, PID: 24821368
    • Mizobe M, Hokimoto S, Akasaka T, Arima Y, Kaikita K, Morita K, Miyazaki H, Oniki K, Nakagawa K, Ogawa H. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. Thromb Res. 2014;134(1):72–7. doi:10.1016/j.thromres.2014.04.020.
    • (2014) Thromb Res. , vol.134 , Issue.1 , pp. 72-77
    • Mizobe, M.1    Hokimoto, S.2    Akasaka, T.3    Arima, Y.4    Kaikita, K.5    Morita, K.6    Miyazaki, H.7    Oniki, K.8    Nakagawa, K.9    Ogawa, H.10
  • 185
    • 81255163189 scopus 로고    scopus 로고
    • Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease
    • COI: 1:CAS:528:DC%2BC38XmtFGrtA%3D%3D, PID: 22093501
    • Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol. 2011;58(22):2263–9.
    • (2011) J Am Coll Cardiol. , vol.58 , Issue.22 , pp. 2263-2269
    • Basra, S.S.1    Tsai, P.2    Lakkis, N.M.3
  • 186
    • 84875239174 scopus 로고    scopus 로고
    • Chronic kidney disease—is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
    • COI: 1:CAS:528:DC%2BC3sXht1yhtb8%3D, PID: 23340097
    • Leng WX, Ren JW, Cao J, Cong YL, Cui H, Hu GL, et al. Chronic kidney disease—is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease? Thromb Res. 2013;131(3):218–24.
    • (2013) Thromb Res. , vol.131 , Issue.3 , pp. 218-224
    • Leng, W.X.1    Ren, J.W.2    Cao, J.3    Cong, Y.L.4    Cui, H.5    Hu, G.L.6
  • 187
    • 79961047447 scopus 로고    scopus 로고
    • Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels
    • COI: 1:CAS:528:DC%2BC3MXhtFKntrjE, PID: 21544318
    • Voisin S, Bongard V, Tidjane MA, Lhermusier T, Carrie D, Sie P. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost. 2011;106(2):227–9.
    • (2011) Thromb Haemost. , vol.106 , Issue.2 , pp. 227-229
    • Voisin, S.1    Bongard, V.2    Tidjane, M.A.3    Lhermusier, T.4    Carrie, D.5    Sie, P.6
  • 188
    • 84879210083 scopus 로고    scopus 로고
    • Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus
    • COI: 1:CAS:528:DC%2BC3sXps1ygur4%3D, PID: 23143668
    • Tello-Montoliu A, Ferreiro JL, Kodali MK, Ueno M, Tomasello SD, Rollini F, et al. Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. J Thromb Thrombolysis. 2013;36(1):14–7.
    • (2013) J Thromb Thrombolysis. , vol.36 , Issue.1 , pp. 14-17
    • Tello-Montoliu, A.1    Ferreiro, J.L.2    Kodali, M.K.3    Ueno, M.4    Tomasello, S.D.5    Rollini, F.6
  • 189
    • 84857637420 scopus 로고    scopus 로고
    • Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention
    • COI: 1:CAS:528:DC%2BC38XivVOqsL0%3D, PID: 22154314
    • Motovska Z, Odvodyova D, Fischerova M, Stepankova S, Maly M, Morawska P, et al. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. Am J Cardiol. 2012;109(5):620–3.
    • (2012) Am J Cardiol. , vol.109 , Issue.5 , pp. 620-623
    • Motovska, Z.1    Odvodyova, D.2    Fischerova, M.3    Stepankova, S.4    Maly, M.5    Morawska, P.6
  • 190
    • 78149357797 scopus 로고    scopus 로고
    • Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome
    • COI: 1:CAS:528:DC%2BC3cXhtl2gtrbL, PID: 20828794
    • Cuisset T, Frere C, Moro PJ, Quilici J, Pons C, Gaborit B, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome. Thromb Res. 2010;126(5):e400–2.
    • (2010) Thromb Res. , vol.126 , Issue.5 , pp. e400-e402
    • Cuisset, T.1    Frere, C.2    Moro, P.J.3    Quilici, J.4    Pons, C.5    Gaborit, B.6
  • 191
    • 84879668006 scopus 로고    scopus 로고
    • Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
    • COI: 1:CAS:528:DC%2BC3sXhtFKls7jO, PID: 23677380
    • Baber U, Bander J, Karajgikar R, Yadav K, Hadi A, Theodoropolous K, et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013;110(1):118–23.
    • (2013) Thromb Haemost. , vol.110 , Issue.1 , pp. 118-123
    • Baber, U.1    Bander, J.2    Karajgikar, R.3    Yadav, K.4    Hadi, A.5    Theodoropolous, K.6
  • 192
    • 65449184492 scopus 로고    scopus 로고
    • Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial]
    • COI: 1:CAS:528:DC%2BD1MXls12htrg%3D, PID: 19427428
    • Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial]. Am J Cardiol. 2009;103(10):1359–63.
    • (2009) Am J Cardiol. , vol.103 , Issue.10 , pp. 1359-1363
    • Dasgupta, A.1    Steinhubl, S.R.2    Bhatt, D.L.3    Berger, P.B.4    Shao, M.5    Mak, K.H.6
  • 193
    • 40849083770 scopus 로고    scopus 로고
    • The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    • COI: 1:CAS:528:DC%2BD1cXktVChtr4%3D, PID: 18371477
    • Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–93.
    • (2008) Am Heart J. , vol.155 , Issue.4 , pp. 687-693
    • Best, P.J.1    Steinhubl, S.R.2    Berger, P.B.3    Dasgupta, A.4    Brennan, D.M.5    Szczech, L.A.6
  • 195
    • 78751605846 scopus 로고    scopus 로고
    • Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel
    • COI: 1:CAS:528:DC%2BC3MXisV2gu74%3D, PID: 21251579
    • Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57(4):399–408.
    • (2011) J Am Coll Cardiol. , vol.57 , Issue.4 , pp. 399-408
    • Morel, O.1    El Ghannudi, S.2    Jesel, L.3    Radulescu, B.4    Meyer, N.5    Wiesel, M.L.6
  • 196
    • 84858330788 scopus 로고    scopus 로고
    • Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis
    • PID: 22431677
    • Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445–59.
    • (2012) Ann Intern Med. , vol.156 , Issue.6 , pp. 445-459
    • Palmer, S.C.1    Di Micco, L.2    Razavian, M.3    Craig, J.C.4    Perkovic, V.5    Pellegrini, F.6
  • 197
    • 77957803601 scopus 로고    scopus 로고
    • Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence
    • PID: 20351550
    • Bauer T, Gitt AK, Junger C, Zahn R, Koeth O, Towae F, et al. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil. 2010;17(5):576–81.
    • (2010) Eur J Cardiovasc Prev Rehabil. , vol.17 , Issue.5 , pp. 576-581
    • Bauer, T.1    Gitt, A.K.2    Junger, C.3    Zahn, R.4    Koeth, O.5    Towae, F.6
  • 198
    • 77953431835 scopus 로고    scopus 로고
    • Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care
    • PID: 20407117
    • Ho PM, Tsai TT, Maddox TM, Powers JD, Carroll NM, Jackevicius C, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes. 2010;3(3):261–6.
    • (2010) Circ Cardiovasc Qual Outcomes. , vol.3 , Issue.3 , pp. 261-266
    • Ho, P.M.1    Tsai, T.T.2    Maddox, T.M.3    Powers, J.D.4    Carroll, N.M.5    Jackevicius, C.6
  • 199
    • 1342310846 scopus 로고    scopus 로고
    • Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative
    • (quiz 678–679)
    • Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc. 2003;43(6):668–78 (quiz 678–679).
    • (2003) J Am Pharm Assoc , vol.43 , Issue.6 , pp. 668-678
    • Krueger, K.P.1    Felkey, B.G.2    Berger, B.A.3
  • 200
    • 84875265119 scopus 로고    scopus 로고
    • Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation
    • PID: 23434769
    • Rinfret S, Rodes-Cabau J, Bagur R, Dery JP, Dorais M, Larose E, et al. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart. 2013;99(8):562–9.
    • (2013) Heart. , vol.99 , Issue.8 , pp. 562-569
    • Rinfret, S.1    Rodes-Cabau, J.2    Bagur, R.3    Dery, J.P.4    Dorais, M.5    Larose, E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.